SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 137 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,113,146 | -1.8% | 76,663 | +42.8% | 0.00% | -100.0% |
| Q2 2023 | $1,133,764 | 0.0% | 53,682 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,133,764 | -23.3% | 53,682 | -7.6% | 0.00% | 0.0% |
| Q4 2022 | $1,478,519 | -99.9% | 58,095 | +34.2% | 0.00% | 0.0% |
| Q3 2022 | $1,040,571,000 | +16.9% | 43,303 | -6.4% | 0.00% | – |
| Q2 2022 | $889,984,000 | +31.7% | 46,257 | +19.0% | 0.00% | – |
| Q1 2022 | $675,595,000 | -20.6% | 38,872 | 0.0% | 0.00% | – |
| Q4 2021 | $850,908,000 | +14.5% | 38,872 | 0.0% | 0.00% | – |
| Q3 2021 | $742,844,000 | +1.4% | 38,872 | -8.9% | 0.00% | – |
| Q2 2021 | $732,678,000 | -14.6% | 42,672 | +11.2% | 0.00% | – |
| Q1 2021 | $858,333,000 | +47.3% | 38,387 | +46.5% | 0.00% | – |
| Q4 2020 | $582,688,000 | – | 26,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |